



Clinical trial results:

A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib

Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2018-004555-21 |
| Trial protocol | BE NL IT |
| Global end of trial date | 02 June 2021 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 (current) |
| This version publication date | 15 January 2023 |
| First version publication date | 15 January 2023 |

Trial information

Trial identification

| | |
|-----------------------|----------|
| Sponsor protocol code | C4221006 |
|-----------------------|----------|

Additional study identifiers

| | |
|------------------------------------|-------------------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Alias ID: ARRAY-818-201 |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Pfizer Inc. |
| Sponsor organisation address | 235 E 42nd Street, New York, United States, 10017 |
| Public contact | Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com |
| Scientific contact | Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 05 July 2022 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 02 June 2021 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

Safety Lead-in: Evaluate the safety of a high-dose regimen of encorafenib + binimetinib combination therapy in subjects with BRAFV600-mutant melanoma who had asymptomatic brain metastasis. Phase 2: 1) If the high-dose regimen was determined to be safe based on results of the Safety Lead-in phase, then evaluate the antitumor activity in brain metastases of the standard and high dose regimens of encorafenib + binimetinib combination therapy in subjects with BRAFV600-mutant melanoma who had asymptomatic brain metastasis; 2) If the high-dose regimen was determined not to be safe based on the results of the Safety Lead-in phase, then evaluate the antitumor activity in brain metastases of the standard dosing regimen of encorafenib + binimetinib combination in subjects with BRAFV600-mutant melanoma who have asymptomatic brain metastasis.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 30 April 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | Argentina: 2 |
| Country: Number of subjects enrolled | Australia: 1 |
| Country: Number of subjects enrolled | Belgium: 1 |
| Country: Number of subjects enrolled | Italy: 1 |
| Country: Number of subjects enrolled | United States: 8 |
| Worldwide total number of subjects | 13 |
| EEA total number of subjects | 2 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|--|---|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 8 |
| From 65 to 84 years | 5 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Study had 2 parts, Safety lead-in (SLI) and Phase 2. In Phase 2, subjects would be randomised either to the standard-dose or high-dose treatment, only if high dose was determined to be safe in safety lead-in.

Pre-assignment

Screening details:

Pfizer and the Steering Committee reviewed safety lead-in data and decided not to evaluate high dose combination of encorafenib + binimetinib in Phase 2 of the study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|---|
| Are arms mutually exclusive? | Yes |
| Arm title | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID |

Arm description:

Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received combination therapy of encorafenib (300 milligram [mg] orally, twice daily [BID]) and binimetinib (45 mg orally, BID) in 28-day cycles and continued until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, or death, whichever occurred first. Subjects were followed up to 30 days after last dose of study drug.

| | |
|--|---------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Encorafenib + Binimetinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule, Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received Encorafenib 300 mg BID and Binimetinib 45 mg BID in 28 days cycle.

| | |
|------------------|--|
| Arm title | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID |
|------------------|--|

Arm description:

Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received standard combination therapy of encorafenib (450 mg orally, once daily [QD]) and binimetinib (45 mg orally, BID) in 28-day cycles and subjects who were able to tolerate the encorafenib 450 mg dose further received 600 mg QD after 4 Weeks. Subjects were followed up to 30 days after last dose of study drug.

| | |
|--|---------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Encorafenib + Binimetinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule, Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received Encorafenib 450 mg QD and Binimetinib 45 mg BID in 28 days cycle.

| Number of subjects in period 1 | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID |
|---------------------------------------|--|---|
| Started | 10 | 3 |
| Completed | 0 | 0 |
| Not completed | 10 | 3 |
| Death | 7 | 3 |
| Unspecified | 1 | - |
| Study termination by sponsor | 2 | - |

Baseline characteristics

Reporting groups

| | |
|--|---|
| Reporting group title | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID |
| Reporting group description: | |
| Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received combination therapy of encorafenib (300 milligram [mg] orally, twice daily [BID]) and binimetinib (45 mg orally, BID) in 28-day cycles and continued until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, or death, whichever occurred first. Subjects were followed up to 30 days after last dose of study drug. | |
| Reporting group title | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID |
| Reporting group description: | |
| Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received standard combination therapy of encorafenib (450 mg orally, once daily [QD]) and binimetinib (45 mg orally, BID) in 28-day cycles and subjects who were able to tolerate the encorafenib 450 mg dose further received 600 mg QD after 4 Weeks. Subjects were followed up to 30 days after last dose of study drug. | |

| Reporting group values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | Total |
|---|--|---|-------|
| Number of subjects | 10 | 3 | 13 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 5 | 3 | 8 |
| From 65-84 years | 5 | 0 | 5 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous Units: Years | | | |
| arithmetic mean | 63.2 | 45.7 | |
| standard deviation | ± 12.94 | ± 5.86 | - |
| Sex: Female, Male Units: Subjects | | | |
| Female | 2 | 1 | 3 |
| Male | 8 | 2 | 10 |
| Race Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 9 | 3 | 12 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |

| | | | |
|-------------------------|---|---|----|
| Ethnicity | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 8 | 2 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |

End points

End points reporting groups

| | |
|--|---|
| Reporting group title | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID |
| Reporting group description: | |
| Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received combination therapy of encorafenib (300 milligram [mg] orally, twice daily [BID]) and binimetinib (45 mg orally, BID) in 28-day cycles and continued until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, or death, whichever occurred first. Subjects were followed up to 30 days after last dose of study drug. | |
| Reporting group title | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID |
| Reporting group description: | |
| Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received standard combination therapy of encorafenib (450 mg orally, once daily [QD]) and binimetinib (45 mg orally, BID) in 28-day cycles and subjects who were able to tolerate the encorafenib 450 mg dose further received 600 mg QD after 4 Weeks. Subjects were followed up to 30 days after last dose of study drug. | |

Primary: Number of Subjects With Dose Limiting Toxicities (DLTs): Safety Lead-in (SLI) Phase

| | |
|--|---|
| End point title | Number of Subjects With Dose Limiting Toxicities (DLTs): Safety Lead-in (SLI) Phase ^{[1][2]} |
| End point description: | |
| DLT: any adverse event (AE) or laboratory abnormality not explained by underlying disease/disease progression/intercurrent illness/concomitant therapies/resulting in inability to tolerate 75% of planned dose of binimetinib or encorafenib during Cycle 1. LVEF >10%, Grade (G) ≥ 3 cardiac disorders; G3/4 hypertension vascular disorders; G3/4 rash, hand foot skin reaction, photosensitivity; G3/4 diarrhea, nausea/vomiting; Total bilirubin (TBL) G ≥ 3 (>3.0*upper limit of normal [ULN]); AST/ALT > 5-8*ULN > 5 days, > 8*ULN, > 3*ULN concurrent TBL > 2*ULN; G ≥ 3 serum creatinine, CK elevation, ECG QTcF prolonged, G3 troponin, electrolyte > 72 hours, G3/4 amylase/lipase. G4 ANC, platelet count > 7 days; G3/4 platelet count, other AE except lymphopenia. G ≥ 3 retinopathy, other disorder > 21 days; G2 uveitis/eye pain/blurred vision/decreased visual acuity; G4 other disorder; Other hematologic/non hematologic G ≥ 3 AE. This endpoint was planned to be analysed in SLI phase only. Dose-determining set included. | |
| End point type | Primary |
| End point timeframe: | |
| Cycle 1 of safety lead-in phase (up to 28 days) | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-----------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 9 | | | |
| Units: Subjects | 3 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Treatment Emergent Adverse Events Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI _CTCAE) Version (v) 4.03: SLI Phase

| | |
|-----------------|--|
| End point title | Number of Subjects With Treatment Emergent Adverse Events Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI _CTCAE) Version (v) 4.03: SLI Phase ^{[3][4]} |
|-----------------|--|

End point description:

AE: any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. TEAEs: events between 1st dose of study drug up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state or start of subsequent anticancer drug therapy-1 day, whichever occurred first. Grades by NCI CTCAE v.4.03:

G1=asymptomatic or mild, clinical or diagnostic observations only, intervention not indicated;

G2=moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); G3=severe or medically significant but not immediately life-threatening, hospitalisation or prolongation of existing hospitalisation indicated, disabling, limiting self-care ADL; G4=life-threatening consequence, urgent intervention indicated; G5=death related to AE.

Subjects with AEs per maximum grades were reported. Safety set: all subjects who received at least 1 dose of any study drug.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Day 1 of dosing up to 30 days after last dose of study drug in SLI Phase, maximum duration up to 10.4 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-----------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Subjects | | | | |
| Grade 1 | 1 | | | |
| Grade 2 | 3 | | | |
| Grade 3 | 5 | | | |
| Grade 4 | 1 | | | |
| Grade 5 | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Hepatology Laboratory Test Abnormalities: SLI Phase

| | |
|-----------------|--|
| End point title | Number of Subjects With Hepatology Laboratory Test |
|-----------------|--|

End point description:

Hepatology laboratory abnormalities included following parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), ALT or AST greater than or equal to (\geq) 3*upper limit normal (ULN), ≥ 5 *ULN, ≥ 10 *ULN, ≥ 20 *ULN; total bilirubin (TBILI): ≥ 2 *ULN; ALT ≥ 3 *ULN and TBILI ≥ 2 *ULN; AST ≥ 3 *ULN and TBILI ≥ 2 *ULN; ALT or AST ≥ 3 *ULN and TBILI ≥ 2 *ULN; ALT or AST ≥ 3 *ULN and TBILI ≥ 2 *ULN and ALP > 2 *ULN; ALT or AST ≥ 3 *ULN and TBILI ≥ 2 *ULN and ALP ≤ 2 *ULN or missing. Only those laboratory test parameters in which at least 1 subject had data were reported. The safety set included all subjects who received at least 1 dose of any study drug. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in SLI Phase, maximum duration up to 10.4 months

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
|-----------------------------|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Subjects | | | | |
| ALT: ≥ 3 *ULN | 3 | | | |
| ALT: ≥ 5 *ULN | 1 | | | |
| AST: ≥ 3 *ULN | 3 | | | |
| ALT or AST: ≥ 3 *ULN | 3 | | | |
| ALT or AST: ≥ 5 *ULN | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Shift From Baseline for Hematology and Coagulation Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: SLI Phase

| | |
|-----------------|--|
| End point title | Number of Subjects With Shift From Baseline for Hematology and Coagulation Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: SLI Phase ^{[7][8]} |
|-----------------|--|

End point description:

Hematology and coagulation laboratory test included: activated partial thromboplastin time prolonged (APTT), anemia, hemoglobin (Hg) increased (inc), international normalised ratio (INR) increased, leukocytosis (Lkc), lymphocyte count decreased (LCD), lymphocyte count increased (LCI), neutrophil count decreased (NCD), platelet count decreased (PCD), and white blood cell decreased (WBCD). Laboratory results were categorically summarised according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of subjects with shift from baseline for hematology and coagulation laboratory test were assessed. Only those laboratory test parameters in which at least 1 subject had data were reported. The safety set included all subjects who received at least 1 dose of any study drug. Here, "n" signifies subjects evaluable for specified rows.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in SLI Phase, maximum duration up to 10.4 months

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
|--|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Subjects | | | | |
| APTP: G0 (baseline) to G0 (post-baseline), n=6 | 5 | | | |
| APTP: G0 (baseline) to G1 (post-baseline), n=6 | 1 | | | |
| Anemia: G0 (baseline) to G0 (post-baseline), n=10 | 2 | | | |
| Anemia: G0 (baseline) to G1 (post-baseline), n=10 | 7 | | | |
| Anemia: G0 (baseline) to G2 (post-baseline), n=10 | 1 | | | |
| Hg inc: G0 (baseline) to G0 (post-baseline), n=10 | 10 | | | |
| INR inc: G0 (baseline) to G0 (post-baseline), n=10 | 10 | | | |
| Lkc: G0 (baseline) to G0 (post-baseline), n=10 | 10 | | | |
| LCD: G0 (baseline) to G0 (post-baseline), n=9 | 2 | | | |
| LCD: G0 (baseline) to G1 (post-baseline), n=9 | 2 | | | |
| LCD: G0 (baseline) to G2 (post-baseline), n=9 | 2 | | | |
| LCD: G0 (baseline) to G3 (post-baseline), n=9 | 3 | | | |
| LCI: G0 (baseline) to G0 (post-baseline), n=9 | 8 | | | |
| LCI: G0 (baseline) to G2 (post-baseline), n=9 | 1 | | | |
| NCD: G0 (baseline) to G0 (post-baseline), n=9 | 8 | | | |
| NCD: G0 (baseline) to G2 (post-baseline), n=9 | 1 | | | |
| PCD: G0 (baseline) to G0 (post-baseline), n=10 | 7 | | | |
| PCD: G0 (baseline) to G1 (post-baseline), n=10 | 3 | | | |
| WBCD: G0 (baseline) to G0 (post-baseline), n=10 | 8 | | | |
| WBCD: G0 (baseline) to G2 (post-baseline), n=10 | 2 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Shift From Baseline for Biochemistry Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: SLI Phase

| | |
|-----------------|---|
| End point title | Number of Subjects With Shift From Baseline for Biochemistry Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: SLI Phase ^{[9][10]} |
|-----------------|---|

End point description:

Biochemistry laboratory test included: alanine aminotransferase increased (AAI), alkaline phosphatase increased (API), aspartate aminotransferase increased (AsAI), blood bilirubin increased (BBI), creatine kinase increased (CKI), creatinine increased (CrI), hypercalcemia (hypercal), hyperglycemia (hypergly), hyperkalemia (hyperkal), hypermagnesemia (hypermag), hyponatremia (hyponat), hypoalbuminemia (hypoalb), hypocalcemia (hypocal), hypoglycemia (hypogly), hypokalemia (hypokal), hypomagnesemia (hypomag), hyponatremia (hyponat), hypophosphatemia (hypophos), lipase increased (LI), and serum amylase increased (SMI). Laboratory results were categorically summarised according to the NCI-CTCAE criteria v4.03. G1= mild; G2= moderate; G3= severe; G4= life-threatening or disabling. Number of subjects with shift from baseline for biochemistry lab test were assessed. Only those lab test parameters in which at least 1 subject had data were reported. Safety set included. Here, n=subjects evaluable for specified rows.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in SLI Phase, maximum duration up to 10.4 months

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| End point values | SLI Phase: Encorafenib 300 mg BID+ Binimetini b 45 mg BID | | | |
|---|---|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Subjects | | | | |
| AAI: G0 (baseline) to G0 (post-baseline), n=8 | 2 | | | |
| AAI: G0 (baseline) to G1 (post-baseline), n=8 | 3 | | | |
| AAI: G0 (baseline) to G2 (post-baseline), n=8 | 2 | | | |
| AAI: G0 (baseline) to G3 (post-baseline), n=8 | 1 | | | |
| AAI: G1 (baseline) to G1 (post-baseline), n=2 | 2 | | | |

| | | | | |
|---|----|--|--|--|
| API: G0 (baseline) to G0 (post-baseline), n=8 | 5 | | | |
| API: G0 (baseline) to G1 (post-baseline), n=8 | 3 | | | |
| API: G1 (baseline) to G0 (post-baseline), n=2 | 2 | | | |
| AsAI: G0 (baseline) to G0 (post-baseline), n=8 | 4 | | | |
| AsAI: G0 (baseline) to G1 (post-baseline), n=8 | 2 | | | |
| AsAI: G0 (baseline) to G2 (post-baseline), n=8 | 2 | | | |
| AsAI: G1 (baseline) to G0 (post-baseline), n=2 | 1 | | | |
| AsAI: G1 (baseline) to G1 (post-baseline), n=2 | 1 | | | |
| BBI: G0 (baseline) to G0 (post-baseline), n=10 | 10 | | | |
| CKI: G0 (baseline) to G0 (post-baseline), n=10 | 6 | | | |
| CKI: G0 (baseline) to G1 (post-baseline), n=10 | 3 | | | |
| CKI: G0 (baseline) to G4 (post-baseline), n=10 | 1 | | | |
| CrI: G0 (baseline) to G1 (post-baseline), n=10 | 9 | | | |
| CrI: G0 (baseline) to G2 (post-baseline), n=10 | 1 | | | |
| Hypercal: G0(baseline) to G0(post-baseline),n=10 | 10 | | | |
| Hypergly:G0(baseline) to G0 (post-baseline),n=8 | 5 | | | |
| Hypergly: G0(baseline) to G1(post-baseline),n=8 | 1 | | | |
| Hypergly: G0(baseline) to G3(post-baseline),n=8 | 2 | | | |
| Hypergly:Baseline to post-baseline,n=2 | 1 | | | |
| Hypergly:Missing(baseline)toG1 (post-baseline)n=2 | 1 | | | |
| Hyperkal:G0(baseline) to G0(post-baseline),n=10 | 10 | | | |
| Hypermag:G0(baseline) to G0(post-baseline),n=10 | 9 | | | |
| Hypermag:G0(baseline) to G1(post-baseline),n=10 | 1 | | | |
| Hypernat:G0(baseline) to G0(post-baseline),n=10 | 10 | | | |
| Hypoalb:G0(baseline) to G0(post-baseline),n=9 | 6 | | | |
| Hypoalb:G0(baseline) to G1(post-baseline),n=9 | 3 | | | |
| Hypoalb:G2(baseline) to G2(post-baseline),n=1 | 1 | | | |
| Hypocal:G0(baseline) to G0(post-baseline),n=10 | 8 | | | |
| Hypocal:G0(baseline) to G1(post-baseline),n=10 | 2 | | | |
| Hypogly:G0(baseline) to G0(post-baseline),n=10 | 10 | | | |
| Hypokal:G0(baseline) to G0(post-baseline),n=10 | 10 | | | |

| | | | | |
|---|----|--|--|--|
| Hypomag:G0(baseline) to G0(post-baseline),n=10 | 10 | | | |
| Hyponat:G0(baseline) to G0(post-baseline),n=8 | 3 | | | |
| Hyponat:G0(baseline) to G1(post-baseline),n=8 | 2 | | | |
| Hyponat:G0(baseline) to G3(post-baseline),n=8 | 3 | | | |
| Hyponat:G1(baseline) to G0(post-baseline),n=2 | 1 | | | |
| Hyponat:G1(baseline) to G3(post-baseline),n=2 | 1 | | | |
| Hypophos:G0(baseline)toG0(post-baseline),n=7 | 6 | | | |
| Hypophos:G0(baseline)toG2(post-baseline),n=7 | 1 | | | |
| Hypophos:Missing(baseline)toG0(post-baseline),n=2 | 1 | | | |
| Hypophos:Missing(baseline)toG2(post-baseline),n=2 | 1 | | | |
| LI: G0(baseline) to G0(post-baseline),n=10 | 7 | | | |
| LI: G0(baseline) to G1(post-baseline),n=10 | 3 | | | |
| SMI: G0(baseline) to G0(post-baseline),n=10 | 10 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Notable Abnormal Vital Signs: SLI Phase

| | |
|-----------------|---|
| End point title | Number of Subjects With Notable Abnormal Vital Signs: SLI Phase ^[11] ^[12] |
|-----------------|---|

End point description:

Vital signs:systolic & diastolic blood pressure (BP),pulse rate,weight & temperature.Systolic & diastolic BP was measured in millimeters of mercury (mmHg) based on criteria: High Systolic BP:>=160 mmHg & increase>=20 mmHg from baseline; High Diastolic BP:>=100 mmHg & increase>=15 mmHg from baseline; Low Systolic BP:<=90 mmHg with decrease from baseline of >=20 mmHg; Low Diastolic BP:<=50 mmHg with decrease from baseline of >=15 mmHg; Pulse rate was measured in beats per minute (bpm) based on criteria:High pulse rate>=120 bpm with increase from baseline of >=15 bpm;Low pulse rate <=50 bpm with decrease from baseline of >=15 bpm;Weight was measured in kilogram (kg) based on criteria:Increase from baseline of >=10%,>=20% decrease from baseline; Temperature was measured in degree Celsius (C) based on criteria:High body temperature>=37.5 degree C,Low body temperature<=36 degree C.Only those vital signs parameters in which at least 1 subject had data were reported.Safety set included.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in SLI Phase, maximum duration up to 10.4 months

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-----------------------------|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Subjects | | | | |
| High systolic BP | 2 | | | |
| Low diastolic BP | 1 | | | |
| High pulse rate | 1 | | | |
| Low pulse rate | 1 | | | |
| Increased body weight | 2 | | | |
| High body temperature | 1 | | | |
| Low body temperature | 3 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Notable Abnormal Electrocardiogram (ECG) Values: SLI Phase

| | |
|-----------------|--|
| End point title | Number of Subjects With Notable Abnormal Electrocardiogram (ECG) Values: SLI Phase ^{[13][14]} |
|-----------------|--|

End point description:

In this endpoint, number of subjects with notable abnormal ECG values included: Fridericia's Correction Formula (QTcF) values in millisecond (msec) based on following criteria: 1) Increase from baseline >30 msec; 2) Increase from baseline >60 msec; 3) New >450 msec; 4) New >480 msec; and 5) New >500 msec; heart rate (HR) values in bpm based on following criteria: 1) Increase from baseline >25% and to a value >100; 2) Decrease from baseline >25% and to a value <50. Only those ECG parameters in which at least 1 subject had data were reported. The safety set included all subjects who received at least 1 dose of any study drug. This endpoint was planned to be analysed in phase 2 only.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in SLI Phase, maximum duration up to 10.4 months

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---------------------------------------|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Subjects | | | | |
| QTcF: New >450 msec | 6 | | | |
| QTcF: Increase from baseline >30 msec | 5 | | | |

| | | | | |
|--|---|--|--|--|
| HR:Increase from baseline >25% & to a value >100 | 1 | | | |
|--|---|--|--|--|

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Incidence of Dose Interruptions, Dose Modifications and Discontinuations due to AEs: SLI Phase

| | |
|-----------------|--|
| End point title | Number of Subjects With Incidence of Dose Interruptions, Dose Modifications and Discontinuations due to AEs: SLI Phase ^{[15][16]} |
|-----------------|--|

End point description:

An AE is any untoward medical occurrence in clinical investigation subject administered a product or medical device; event need not necessarily to have a causal relationship with treatment or usage. In this endpoint, number of subjects with incidence of dose interruptions, dose modifications and discontinuations due to AEs were reported. The safety set included all subjects who received at least 1 dose of any study drug. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in SLI Phase, maximum duration up to 10.4 months

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Subjects | | | | |
| Dose interruptions due to AE | 6 | | | |
| Dose modifications due to AE | 4 | | | |
| Discontinuations due to AE | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Brain Metastasis Response Rate (BMRR) Based on Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (mRECIST v1.1): Phase 2

| | |
|-----------------|--|
| End point title | Brain Metastasis Response Rate (BMRR) Based on Modified Response Evaluation Criteria in Solid Tumors Version 1.1 |
|-----------------|--|

End point description:

BMRR was reported in terms of percentage of subjects who achieved a confirmed best overall response (BOR) of confirmed complete response (CR) or partial response (PR) in brain metastasis per mRECIST v1.1 from date of first dose until disease progression, death due to any cause, or start of subsequent anticancer therapy, whichever occurred first. BOR: best response recorded from date of first dose of study treatment until progression by investigator assessment at each time point. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum of diameters recorded since treatment started. In addition, sum must have absolute increase of at least 5 mm. The safety set included all subjects who received at least 1 dose of any study drug.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From date of first dose until disease progression, death due to any cause or subsequent therapy initiation, whichever occurred first in Phase 2 (approximately up to 8.3 months)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analysed for this endpoint.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Phase 2 arm was planned to be analysed for this endpoint.

| End point values | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | | |
|----------------------------------|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3 | | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 66.7 (9.4 to 99.2) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Extracranial Response Rate Based on RECIST v1.1: SLI Phase and Phase 2

| | |
|-----------------|--|
| End point title | Extracranial Response Rate Based on RECIST v1.1: SLI Phase and Phase 2 |
|-----------------|--|

End point description:

Extracranial response rate was defined as the percentage of subjects with a BOR of confirmed CR or confirmed PR in extracranial lesions by investigator assessment per RECIST v1.1. BOR: best response recorded from date of first dose of study treatment until progression by investigator assessment at each time point. CR: disappearance of all target lesions. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum of diameters recorded since treatment started. In addition, sum must have absolute increase of at least 5 mm. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The safety set included all subjects who received at least 1 dose of any study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose until disease progression, death due to any cause or subsequent therapy

initiation, whichever occurred first in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
|----------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 3 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 60.0 (26.2 to 87.8) | 100 (29.2 to 100) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Global Response Rate: SLI Phase and Phase 2

| | |
|-----------------|---|
| End point title | Global Response Rate: SLI Phase and Phase 2 |
|-----------------|---|

End point description:

Global response rate was defined as the percentage of subjects with a BOR of confirmed CR or confirmed PR by investigator assessment in brain metastasis and extracranial lesions per combined mRECIST v1.1 and RECIST v1.1, respectively. BOR: best response recorded from date of first dose of study treatment until progression by investigator assessment at each time point. CR: disappearance of all target lesions. Any pathological lymph nodes must be <10 mm on the short axis. PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum of the diameters (e.g., percent change from baseline). PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum of diameters recorded since treatment started. In addition, sum must have absolute increase of at least 5 mm. The safety set included all subjects who received at least 1 dose of any study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose until disease progression, death due to any cause or subsequent therapy initiation, whichever occurred first in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
|----------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 3 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 50.0 (18.7 to 81.3) | 100 (29.2 to 100) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR) for Brain Metastasis Response Based on mRECIST v1.1: SLI Phase and Phase 2

| | |
|-----------------|---|
| End point title | Disease Control Rate (DCR) for Brain Metastasis Response Based on mRECIST v1.1: SLI Phase and Phase 2 |
|-----------------|---|

End point description:

DCR was defined as the percentage of subjects with a BOR of CR, PR or stable disease (SD) by investigator assessment per mRECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters recorded since the treatment started. The safety set included all subjects who received at least 1 dose of any study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose until disease progression, death due to any cause or subsequent therapy initiation, whichever occurred first in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
|----------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 3 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 100 (69.2 to 100) | 100 (29.2 to 100) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: DCR for Extracranial Response Based on RECIST v1.1: SLI Phase and Phase 2

| | |
|-----------------|---|
| End point title | DCR for Extracranial Response Based on RECIST v1.1: SLI Phase and Phase 2 |
|-----------------|---|

End point description:

DCR was defined as the percentage of subjects with a BOR of CR, PR or SD by Investigator assessment per RECIST v1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of

diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum demonstrates an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. The safety set included all subjects who received at least 1 dose of any study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose until disease progression, death due to any cause or subsequent therapy initiation, whichever occurred first in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
|----------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 3 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 70.0 (34.8 to 93.3) | 100 (29.2 to 100) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: DCR for Global Response: SLI Phase and Phase 2

| | |
|-----------------|--|
| End point title | DCR for Global Response: SLI Phase and Phase 2 |
|-----------------|--|

End point description:

DCR was defined as the percentage of subjects with a BOR of CR, PR or SD by Investigator assessment per RECIST v1.1. CR: disappearance of all target lesions. Any pathological lymph nodes must be <10 mm on the short axis. PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum of the diameters (e.g., percent change from baseline). SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for PD. PD: at least a 20% increase in the sum of the diameters of target lesions, taking as a reference the smallest sum of diameters recorded since the treatment started (i.e., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of at least 5 mm. The safety set included all subjects who received at least 1 dose of any study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose until disease progression, death due to any cause or subsequent therapy initiation, whichever occurred first in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| | | | | |
|----------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 3 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 90.0 (55.5 to 99.7) | 100 (29.2 to 100) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR) for Brain Metastasis Response Based on mRECIST v1.1: SLI Phase and Phase 2

| | |
|-----------------|---|
| End point title | Duration of Response (DOR) for Brain Metastasis Response Based on mRECIST v1.1: SLI Phase and Phase 2 |
|-----------------|---|

End point description:

DOR: time from date of first radiographic response (CR or PR) to earliest documented disease progression or death due to any cause. CR: disappearance of all target lesions. PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum of diameters recorded since treatment started. In addition, sum must have absolute increase of at least 5 mm. DOR (months)=(date of event or censoring – date of first CR or PR + 1)/30.4375. If subject with CR or PR did not have an event at time of analysis cutoff or with an event more than 16 weeks (for first 11 cycles after treatment start date) or 24 weeks (after Cycle 11) after last adequate tumor assessment, subject was censored on date of last adequate tumor assessment that documented no progression. Safety set included all subjects who received at least 1 dose of any study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first radiographic response (CR or PR) to earliest documented disease progression or death due to any cause in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| | | | | |
|----------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 3 | | |
| Units: Months | | | | |
| median (confidence interval 95%) | 3.3 (2.8 to 8.5) | 5.6 (5.0 to 6.2) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: DOR for Global Response: SLI Phase and Phase 2

| | |
|---|--|
| End point title | DOR for Global Response: SLI Phase and Phase 2 |
| End point description: DOR: time from date of first radiographic response (CR or PR) to earliest documented disease progression or death due to any cause. CR: disappearance of all target lesions. PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum of diameters recorded since treatment started. In addition, sum must have absolute increase of at least 5 mm. DOR (months) = (date of event or censoring – date of first CR or PR + 1)/30.4375. If a subject with CR or PR did not have an event at time of analysis cutoff or with an event more than 16 weeks (for first 11 cycles after treatment start date) or 24 weeks (after Cycle 11) after last adequate tumor assessment, subject was censored on date of last adequate tumor assessment that documented no progression. Safety set included all subjects who received at least 1 dose of any study drug. | |
| End point type | Secondary |
| End point timeframe: From date of first radiographic response (CR or PR) to earliest documented disease progression or death due to any cause in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months) | |

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
|----------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 3 | | |
| Units: Months | | | | |
| median (confidence interval 95%) | 2.9 (2.8 to 8.5) | 5.0 (3.9 to 6.2) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS) for Brain Metastasis Based on mRECIST v1.1: SLI Phase and Phase 2

| | |
|--|---|
| End point title | Progression Free Survival (PFS) for Brain Metastasis Based on mRECIST v1.1: SLI Phase and Phase 2 |
| End point description: PFS was defined as the time from date of the first dose of study treatment to the earliest documented disease progression (PD) by Investigator assessment, or death due to any cause, whichever occurs first. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase of at least 5 mm. If a subject did not had a PFS event at the time of the analysis cutoff or at the start of any new anticancer therapy, PFS was censored at the date of last adequate tumor assessment. Data for this endpoint was not evaluated, due to limited number of subjects who had event. | |
| End point type | Secondary |
| End point timeframe: From date of first dose of study treatment to the earliest documented disease progression by investigator assessment, or death due to any cause, whichever occurs first in SLI (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months) | |

| | | | | |
|----------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[19] | 0 ^[20] | | |
| Units: Months | | | | |
| median (confidence interval 95%) | (to) | (to) | | |

Notes:

[19] - Data was not evaluated, due to limited number of subjects who had event.

[20] - Data was not evaluated, due to limited number of subjects who had event.

Statistical analyses

No statistical analyses for this end point

Secondary: DOR for Extracranial Response Based on RECIST v1.1: SLI Phase and Phase 2

| | |
|-----------------|---|
| End point title | DOR for Extracranial Response Based on RECIST v1.1: SLI Phase and Phase 2 |
|-----------------|---|

End point description:

DOR: time from date of first radiographic response (CR or PR) to earliest documented disease progression or death due to any cause. CR: disappearance of all target lesions. PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum of diameters recorded since treatment started. In addition, sum must have absolute increase of at least 5 mm. DOR (months) = (date of event or censoring – date of first CR or PR + 1)/30.4375. If a subject with CR or PR did not have an event at time of analysis cutoff or with an event more than 16 weeks (for first 11 cycles after treatment start date) or 24 weeks (after Cycle 11) after last adequate tumor assessment, subject was censored on date of last adequate tumor assessment that documented no progression. Data for this endpoint was not evaluated, due to limited number of subjects who had event.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first radiographic response (CR or PR) to earliest documented disease progression or death due to any cause in SLI Phase (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| | | | | |
|----------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[21] | 0 ^[22] | | |
| Units: Months | | | | |
| median (confidence interval 95%) | (to) | (to) | | |

Notes:

[21] - Data was not evaluated, due to limited number of subjects who had event.

[22] - Data was not evaluated, due to limited number of subjects who had event.

Statistical analyses

No statistical analyses for this end point

Secondary: PFS for Global Tumor Assessment: SLI Phase and Phase 2

| | |
|-----------------|--|
| End point title | PFS for Global Tumor Assessment: SLI Phase and Phase 2 |
|-----------------|--|

End point description:

PFS was defined as the time from date of the first dose of study treatment to the earliest documented disease progression (PD) by Investigator assessment, or death due to any cause, whichever occurs first. PD: at least a 20% increase in the sum of the diameters of target lesions, taking as a reference the smallest sum of diameters recorded since the treatment started (i.e., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of at least 5 mm. Global tumor assessment consists of brain metastasis and extracranial lesions. If a subject did not have a PFS event at the time of the analysis cutoff or at the start of any new anticancer therapy, PFS was censored at the date of last adequate tumor assessment. Data for this outcome measure was not evaluated, due to limited number of subjects who had event.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose of study treatment to the earliest documented disease progression by investigator assessment, or death due to any cause, whichever occurs first in SLI (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
|----------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[23] | 0 ^[24] | | |
| Units: Months | | | | |
| median (confidence interval 95%) | (to) | (to) | | |

Notes:

[23] - Data was not evaluated, due to limited number of subjects who had event.

[24] - Data was not evaluated, due to limited number of subjects who had event.

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival: Safety Lead-in Phase and Phase 2

| | |
|-----------------|--|
| End point title | Overall Survival: Safety Lead-in Phase and Phase 2 |
|-----------------|--|

End point description:

Overall survival (OS) was defined as the time from date of the first dose of study treatment to the date of death due to any cause. If a death was not observed by the date of the analysis cutoff, OS was censored at the date of last contact. OS (months) = (date of death or censoring – date of first dose +1)/30.4375. Data for this endpoint was not evaluated, due to limited number of subjects who had

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose of study treatment to the earliest documented disease progression by investigator assessment, or death due to any cause, whichever occurs first in SLI (approximately up to 10.4 months) and Phase 2 (approximately up to 8.3 months)

| | | | | |
|--------------------------------------|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[25] | 0 ^[26] | | |
| Units: Months | | | | |
| arithmetic mean (standard deviation) | () | () | | |

Notes:

[25] - Data was not evaluated, due to limited number of subjects who had event.

[26] - Data was not evaluated, due to limited number of subjects who had event.

Statistical analyses

No statistical analyses for this end point

Secondary: BMRR Based on mRECIST v1.1: SLI Phase

| | |
|-----------------|---|
| End point title | BMRR Based on mRECIST v1.1: SLI Phase ^[27] |
|-----------------|---|

End point description:

BMRR: percentage of subjects who achieved a confirmed best overall response (BOR) of confirmed CR or PR in brain metastasis per mRECIST v1.1 from date of first dose until disease progression, death due to any cause, or start of subsequent anticancer therapy, whichever occurs first. BOR: best response recorded from date of first dose of study treatment until progression by investigator assessment at each time point. CR: Disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters (e.g., percent change from baseline). The safety set included all subjects who received at least 1 dose of any study drug. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of first dose until disease progression, death due to any cause or subsequent therapy initiation, whichever occurred first in SLI Phase (approximately up to 10.4 months)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|----------------------------------|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 | | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 60.0 (26.2 to 87.8) | | | |

Statistical analyses

Secondary: Number of Subjects With Treatment Emergent AEs of Maximum Severity Grades Based on NCI CTCAE v4.03: Phase 2

| | |
|-----------------|---|
| End point title | Number of Subjects With Treatment Emergent AEs of Maximum Severity Grades Based on NCI CTCAE v4.03: Phase 2 ^[28] |
|-----------------|---|

End point description:

AE: any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. TEAEs: event between 1st dose of study drug up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state or start of subsequent anticancer drug therapy 1 day, whichever occurred first. Grades by NCI CTCAE v.4.03:

G1=asymptomatic or mild, clinical or diagnostic observations only, intervention not indicated; G2=moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental ADL); G3=severe or medically significant but not immediately life-threatening, hospitalisation or prolongation of existing hospitalisation indicated, disabling, limiting self-care ADL; G4=life-threatening consequence, urgent intervention indicated; G5=death related to AE. Only those categories in which at least 1 subject had data were reported. Safety set: all subjects who received at least 1 dose of any study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 of dosing up to 30 days after last dose of study drug in Phase 2, maximum duration up to 8.3 months

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Phase 2 arm was planned to be analysed for this endpoint.

| | | | | |
|-----------------------------|--|--|--|--|
| End point values | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3 | | | |
| Units: Subjects | | | | |
| Grade 2 | 2 | | | |
| Grade 4 | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Hepatology Laboratory Test Abnormalities: Phase 2

| | |
|-----------------|---|
| End point title | Number of Subjects With Hepatology Laboratory Test Abnormalities: Phase 2 ^[29] |
|-----------------|---|

End point description:

Hepatology laboratory abnormalities included following parameters: ALT, AST, ALT or AST $\geq 3 \times \text{ULN}$, $\geq 5 \times \text{ULN}$, $\geq 10 \times \text{ULN}$, $\geq 20 \times \text{ULN}$; TBILI: $\geq 2 \times \text{ULN}$; ALT $\geq 3 \times \text{ULN}$ and TBILI $\geq 2 \times \text{ULN}$; AST $\geq 3 \times \text{ULN}$ and TBILI $\geq 2 \times \text{ULN}$; ALT or AST $\geq 3 \times \text{ULN}$ and TBILI $\geq 2 \times \text{ULN}$; ALT or AST $\geq 3 \times \text{ULN}$ and TBILI $\geq 2 \times \text{ULN}$ and ALP $> 2 \times \text{ULN}$; ALT or AST $\geq 3 \times \text{ULN}$ and TBILI $\geq 2 \times \text{ULN}$ and ALP $\leq 2 \times \text{ULN}$ or missing. Only those laboratory test parameters in which at least 1 subject had data were reported. The safety set included all subjects who received at least 1 dose of any study drug. This endpoint was planned to be analysed in phase 2 only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in Phase 2, maximum duration up to 8.3 months

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Phase 2 arm was planned to be analysed for this endpoint.

| End point values | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | | |
|---|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3 | | | |
| Units: Subjects | | | | |
| ALT: $\geq 3 \times \text{ULN}$ | 2 | | | |
| ALT: $\geq 5 \times \text{ULN}$ | 1 | | | |
| ALT: $\geq 10 \times \text{ULN}$ | 1 | | | |
| ALT: $\geq 20 \times \text{ULN}$ | 1 | | | |
| AST: $\geq 3 \times \text{ULN}$ | 1 | | | |
| AST: $\geq 5 \times \text{ULN}$ | 1 | | | |
| AST: $\geq 10 \times \text{ULN}$ | 1 | | | |
| ALT or AST: $\geq 3 \times \text{ULN}$ | 2 | | | |
| ALT or AST: $\geq 5 \times \text{ULN}$ | 1 | | | |
| ALT or AST: $\geq 10 \times \text{ULN}$ | 1 | | | |
| ALT or AST: $\geq 20 \times \text{ULN}$ | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Shift From Baseline for Hematology and Coagulation Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: Phase 2

| | |
|-----------------|--|
| End point title | Number of Subjects With Shift From Baseline for Hematology and Coagulation Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: Phase 2 ^[30] |
|-----------------|--|

End point description:

Hematology and coagulation laboratory test included: activated partial thromboplastin time prolonged (APTT), anemia, hemoglobin (Hg) increased (inc), international normalised ratio (INR) increased, leukocytosis (Lkc), lymphocyte count decreased (LCD), lymphocyte count increased (LCI), neutrophil count decreased (NCD), platelet count decreased (PCD), and white blood cell decreased (WBCD). Laboratory results were categorically summarised according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of subjects with shift from baseline for hematology and coagulation laboratory test were assessed. Only those laboratory test parameters in which at least 1 subject had data were reported. The safety set included all subjects who received at least 1 dose of any study drug. Here, "n" signifies subjects evaluable for specified rows.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in Phase 2, maximum duration up to 8.3 months

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Phase 2 arm was planned to be analysed for this endpoint.

| End point values | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | | |
|---|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3 | | | |
| Units: Subjects | | | | |
| APTTP: G0 (baseline) to G0 (post-baseline), n=1 | 1 | | | |
| Anemia: G0 (baseline) to G1 (post-baseline), n=2 | 1 | | | |
| Anemia: G0 (baseline) to G2 (post-baseline), n=2 | 1 | | | |
| Anemia: G1 (baseline) to G1 (post-baseline), n=1 | 1 | | | |
| Hg inc: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| INR inc: G0 (baseline) to G0 (post-baseline), n=1 | 1 | | | |
| Lkc: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| LCD: G0 (baseline) to G0 (post-baseline), n=3 | 2 | | | |
| LCD: G0 (baseline) to G1 (post-baseline), n=3 | 1 | | | |
| LCI: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| NCD: G0 (baseline) to G0 (post-baseline), n=3 | 2 | | | |
| NCD: G0 (baseline) to G2 (post-baseline), n=3 | 1 | | | |
| PCD: G0 (baseline) to G0 (post-baseline), n=3 | 2 | | | |
| PCD: G0 (baseline) to G1 (post-baseline), n=3 | 1 | | | |
| WBCD: G0 (baseline) to G0 (post-baseline), n=3 | 2 | | | |
| WBCD: G0 (baseline) to G1 (post-baseline), n=3 | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Shift From Baseline for Biochemistry Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: Phase 2

| | |
|-----------------|--|
| End point title | Number of Subjects With Shift From Baseline for Biochemistry Laboratory Test Abnormalities Based on NCI-CTCAE v4.03: Phase 2 ^[31] |
|-----------------|--|

End point description:

Biochemistry laboratory test included: alanine aminotransferase increased (AAI), alkaline phosphatase increased (API), aspartate aminotransferase increased (AsAI), blood bilirubin increased (BBI), creatine kinase increased (CKI), creatinine increased (CrI), hypercalcemia (hypercal), hyperglycemia (hypergly), hyperkalemia (hyperkal), hypermagnesemia (hypermag), hypernatremia (hypernat), hypoalbuminemia (hypoalb), hypocalcemia (hypocal), hypoglycemia (hypogly), hypokalemia (hypokal), hypomagnesemia (hypomag), hyponatremia (hyponat), hypophosphatemia (hypophos), lipase increased (LI), and serum amylase increased (SMI). Laboratory results were categorically summarised according to the NCI-CTCAE criteria v4.03. G1= mild; G2= moderate; G3= severe; G4= life-threatening or disabling. Number of subjects with shift from baseline for biochemistry lab test were assessed. Only those lab test parameters in which at least 1 subject had data were reported. Safety set included. Here, n=subjects evaluable for specified rows.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in Phase 2, maximum duration up to 8.3 months

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Phase 2 arm was planned to be analysed for this endpoint.

| End point values | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | | |
|--|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3 | | | |
| Units: Subjects | | | | |
| AAI: G0 (baseline) to G2 (post-baseline), n=1 | 1 | | | |
| AAI: G1 (baseline) to G0 (post-baseline), n=2 | 1 | | | |
| AAI: G1 (baseline) to G4 (post-baseline), n=2 | 1 | | | |
| API: G0 (baseline) to G0 (post-baseline), n=2 | 1 | | | |
| API: G0 (baseline) to G1 (post-baseline), n=2 | 1 | | | |
| API: G2 (baseline) to G2 (post-baseline), n=1 | 1 | | | |
| AsAI: G0 (baseline) to G1 (post-baseline), n=2 | 1 | | | |
| AsAI: G0 (baseline) to G3 (post-baseline), n=2 | 1 | | | |
| AsAI: G1 (baseline) to G0 (post-baseline), n=1 | 1 | | | |
| BBI: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| CK inc: G0 (baseline) to G1 (post-baseline), n=3 | 2 | | | |
| CK inc: G0 (baseline) to G2 (post-baseline), n=3 | 1 | | | |
| CrI: G0 (baseline) to G1 (post-baseline), n=3 | 1 | | | |
| CrI: G0 (baseline) to G2 (post-baseline), n=3 | 2 | | | |
| Hypercal: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| Hypergly: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |

| | | | | |
|--|---|--|--|--|
| Hyperkal: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| Hypermag: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| Hypernat: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| Hypoalb: G0 (baseline) to G0 (post-baseline), n=2 | 2 | | | |
| Hypoalb: G1 (baseline) to G0 (post-baseline), n=1 | 1 | | | |
| Hypocal: G0 (baseline) to G0 (post-baseline), n=3 | 1 | | | |
| Hypocal: G0 (baseline) to G1 (post-baseline), n=3 | 2 | | | |
| Hypogly: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| Hypokal: G0 (baseline) to G0 (post-baseline), n=3 | 2 | | | |
| Hypokal: G0 (baseline) to G1 (post-baseline), n=3 | 1 | | | |
| Hypomag: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| Hyponat: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| Hypophos: G0 (baseline) to G0 (post-baseline), n=3 | 3 | | | |
| LI: G0 (baseline) to G0 (post-baseline), n=3 | 2 | | | |
| LI: G0 (baseline) to G1 (post-baseline), n=3 | 1 | | | |
| SAI: G0 (baseline) to G0 (post-baseline), n=3 | 2 | | | |
| SAI: G0 (baseline) to G1 (post-baseline), n=3 | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Clinically Significant Change in Notable Abnormal Vital Signs: Phase 2

| | |
|-----------------|--|
| End point title | Number of Subjects With Clinically Significant Change in Notable Abnormal Vital Signs: Phase 2 ^[32] |
|-----------------|--|

End point description:

Vital signs: systolic & diastolic BP, pulse rate, weight & temperature. Systolic & diastolic BP was measured in mmHg based on criteria: High Systolic BP: ≥ 160 mmHg & increase ≥ 20 mmHg from baseline; High Diastolic BP: ≥ 100 mmHg & increase ≥ 15 mmHg from baseline; Low Systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; Low Diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; Pulse rate was measured in bpm based on criteria: High pulse rate ≥ 120 bpm with increase from baseline of ≥ 15 bpm; Low pulse rate ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; Weight was measured in kg based on criteria: Increase from baseline of $\geq 10\%$; $\geq 20\%$ decrease from baseline; Temperature was measured in degree C based on criteria: High body temperature ≥ 37.5 degree C, Low body temperature ≤ 36 degree C. Only those vital signs parameters in which at least 1 subject had data were reported. Safety set included.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in Phase 2, maximum duration up to 8.3 months

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Phase 2 arm was planned to be analysed for this endpoint.

| | | | | |
|-----------------------------|--|--|--|--|
| End point values | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3 | | | |
| Units: Subjects | | | | |
| Increased body weight | 1 | | | |
| Low body temperature | 2 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Notable Abnormal Electrocardiogram (ECG) Values: Phase 2

| | |
|-----------------|--|
| End point title | Number of Subjects With Notable Abnormal Electrocardiogram (ECG) Values: Phase 2 ^[33] |
|-----------------|--|

End point description:

In this end point, number of subjects with notable abnormal ECG values included: QTcF values in msec based on following criteria: 1) increase from baseline >30 msec; 2) increase from baseline >60 msec; 3) new >450 msec; 4) new >480 msec; and 5) new >500 msec; heart rate values in bpm based on following criteria: 1) Increase from baseline >25% and to a value >100; 2) Decrease from baseline >25% and to a value <50. Only those vital ECG parameters in which at least 1 subject had data were reported. The safety set included all subjects who received at least 1 dose of any study drug. This endpoint was planned to be analysed in phase 2 only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) up to 30 days after last dose of study drug in Phase 2, maximum duration up to 8.3 months

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Phase 2 arm was planned to be analysed for this endpoint.

| | | | | |
|----------------------------------|--|--|--|--|
| End point values | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3 | | | |
| Units: Subjects | | | | |
| QTcF: Increase from baseline >30 | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|---|
| End point title | Plasma Concentrations of Encorafenib and its Metabolite LHY746: SLI Phase ^[34] |
|-----------------|---|

End point description:

In this end point, plasma concentrations (in nanogram per milliliter [ng/mL]) of encorafenib and its metabolite LHY746 at Cycle 1 Day 1 (C1D1), Cycle 1 Day 15 (C1D15), Cycle 2 Day 1 (C2D1), and Cycle 3 Day 1 (C3D1) at different time points were reported. The pharmacokinetic (PK) analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose, Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose, Cycle 2, Cycle 3 Day 1: Pre-dose

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
|---|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib C1D1: 0.5 hrs post dose, n=8 | 65.5 (± 328.8) | | | |
| Encorafenib C1D1: 1.5 hrs post dose, n=8 | 1830 (± 325.5) | | | |
| Encorafenib C1D1: 3 hrs post dose, n=8 | 2120 (± 36.3) | | | |
| Encorafenib C1D1: 6 hrs post dose, n=7 | 1170 (± 67.7) | | | |
| Encorafenib C1D15: pre-dose, n=6 | 92.3 (± 87.9) | | | |
| Encorafenib C1D15: 0.5 hrs post dose, n=6 | 182 (± 243.5) | | | |
| Encorafenib C1D15: 1.5 hrs post dose, n=6 | 745 (± 132.7) | | | |
| Encorafenib C1D15: 3 hrs post dose, n=6 | 953 (± 50.0) | | | |
| Encorafenib C1D15: 6 hrs post dose, n=6 | 332 (± 61.0) | | | |
| Encorafenib C2D1: pre-dose, n=4 | 59.7 (± 65.7) | | | |
| Encorafenib C3D1: pre-dose, n=5 | 50.1 (± 47.8) | | | |
| LHY746 C1D1: 0.5 hrs post dose, n=8 | 6.46 (± 114.1) | | | |
| LHY746 C1D1: 1.5 hrs post dose, n=8 | 123 (± 345.5) | | | |
| LHY746 C1D1: 3 hrs post dose, n=6 | 296 (± 46.7) | | | |
| LHY746 C1D1: 6 hrs post dose, n=7 | 277 (± 62.7) | | | |
| LHY746 C1D15: pre-dose, n=6 | 892 (± 101.1) | | | |

| | | | | |
|--------------------------------------|---------------------|--|--|--|
| LHY746 C1D15: 0.5 hrs post dose, n=6 | 941 (\pm 88.2) | | | |
| LHY746 C1D15: 1.5 hrs post dose, n=6 | 1040 (\pm 93.4) | | | |
| LHY746 C1D15: 3 hrs post dose, n=8 | 1690 (\pm 64.3) | | | |
| LHY746 C1D15: 6 hrs post dose, n=6 | 1520 (\pm 59.0) | | | |
| LHY746 C2D1: pre-dose, n=4 | 655 (\pm 91.3) | | | |
| LHY746 C3D1: pre-dose, n=5 | 256 (\pm 2956.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|---|
| End point title | Plasma Concentrations of Binimetinib and its Metabolite AR00426032: SLI Phase ^[35] |
|-----------------|---|

End point description:

In this end point, plasma concentrations of binimetinib and its metabolite AR00426032 at C1D1, C1D15, C2D1, and C3D1 at different time points were reported. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose: Cycle 2, Cycle 3 Day 1: Pre-dose

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib C1D1: 0.5 hrs post dose, n=8 | 86.6 (\pm 567.4) | | | |
| Binimetinib C1D1: 1.5 hrs post dose, n=8 | 297 (\pm 341.9) | | | |
| Binimetinib C1D1: 3 hrs post dose, n=8 | 233 (\pm 83.2) | | | |
| Binimetinib C1D1: 6 hrs post dose, n=7 | 151 (\pm 91.6) | | | |
| Binimetinib C1D15: pre-dose, n=6 | 47.7 (\pm 71.8) | | | |
| Binimetinib C1D15: 0.5 hrs post dose, n=6 | 151 (\pm 67.8) | | | |
| Binimetinib C1D15: 1.5 hrs post dose, n=6 | 232 (\pm 121.1) | | | |
| Binimetinib C1D15: 3 hrs post dose, n=6 | 215 (\pm 55.2) | | | |

| | | | | |
|--|----------------|--|--|--|
| Binimetinib C1D15: 6 hrs post dose, n=6 | 79.9 (± 56.6) | | | |
| Binimetinib C2D1: pre-dose, n=4 | 42.0 (± 47.8) | | | |
| Binimetinib C3D1: pre-dose, n=5 | 30.0 (± 65.3) | | | |
| AR00426032 C1D1: 0.5 hrs post dose, n=8 | 8.10 (± 132.4) | | | |
| AR00426032 C1D1: 1.5 hrs post dose, n=8 | 30.3 (± 345.7) | | | |
| AR00426032 C1D1: 3 hrs post dose, n=8 | 31.7 (± 60.1) | | | |
| AR00426032 C1D1: 6 hrs post dose, n=7 | 21.9 (± 36.6) | | | |
| AR00426032 C1D15: pre-dose, n=6 | 3.13 (± 53.0) | | | |
| AR00426032 C1D15: 0.5 hrs post dose, n=6 | 5.89 (± 136.9) | | | |
| AR00426032 C1D15: 1.5 hrs post dose, n=6 | 10.6 (± 56.8) | | | |
| AR00426032 C1D15: 3 hrs post dose, n=6 | 12.5 (± 58.0) | | | |
| AR00426032 C1D15: 6 hrs post dose, n=6 | 4.71 (± 62.8) | | | |
| AR00426032 C2D1: pre-dose, n=4 | 2.97 (± 29.6) | | | |
| AR00426032 C3D1: pre-dose, n=5 | 1.57 (± 42.2) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-Time Curve From Time Zero to 6 Hours (AUC 0-6) of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|--|
| End point title | Area Under the Plasma Concentration-Time Curve From Time Zero to 6 Hours (AUC 0-6) of Encorafenib and its Metabolite LHY746: SLI Phase ^[36] |
|-----------------|--|

End point description:

In this end point, area under the plasma concentration-time curve from zero to 6 hours (AUC 0-6) after administration of encorafenib and its metabolite LHY746 in nanogram*hour per milliliter (ng*hr/mL) at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 7 | | | |
| Units: ng*hr/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib: C1D1, n=7 | 9530 (± 50.6) | | | |
| Encorafenib: C1D15, n=6 | 3930 (± 52.8) | | | |
| LHY746: C1D1, n=7 | 1230 (± 60.1) | | | |
| LHY746: C1D15, n=6 | 8160 (± 67.7) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: AUC0-6 of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|--|
| End point title | AUC0-6 of Binimetinib and its Metabolite AR00426032: SLI Phase ^[37] |
|-----------------|--|

End point description:

In this end point, area under the plasma concentration-time curve from zero to 6 hours (AUC 0-6) after administration of binimetinib and its metabolite AR00426032 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 7 | | | |
| Units: ng*hr/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib: C1D1n =7 | 1410 (± 85.5) | | | |
| Binimetinib: C1D15, n=6 | 1050 (± 39.7) | | | |
| AR00426032: C1D1, n=7 | 159 (± 65.9) | | | |
| AR00426032: C1D15, n=6 | 53.9 (± 48.6) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-Time Curve From Time Zero to last Time Point (AUClast) of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|--|
| End point title | Area Under the Plasma Concentration-Time Curve From Time Zero to last Time Point (AUClast) of Encorafenib and its Metabolite LHY746: SLI Phase ^[38] |
|-----------------|--|

End point description:

In this end point, area under the plasma concentration-time curve from zero to the last measurable time point (AUClast) after administration of encorafenib and its metabolite LHY746 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ng*hr/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib: C1D1, n=8 | 9190 (± 47.8) | | | |
| Encorafenib: C1D15, n=6 | 7490 (± 52.8) | | | |
| LHY746: C1D1, n=8 | 1180 (± 56.9) | | | |
| LHY746: C1D15, n=6 | 29600 (± 73.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: AUClast of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|---|
| End point title | AUClast of Binimetinib and its Metabolite AR00426032: SLI |
|-----------------|---|

End point description:

In this end point, area under the plasma concentration-time curve from zero to the last measurable time point (AUClast) after administration of binimetinib and its metabolite AR00426032 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ng*hr/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib: C1D1, n=8 | 1350 (± 79.1) | | | |
| Binimetinib: C1D15, n=6 | 1440 (± 43.9) | | | |
| AR00426032: C1D1, n=8 | 156 (± 60.6) | | | |
| AR00426032: C1D15, n=6 | 77.9 (± 49.7) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-Time Curve From Time Zero to Tau (AUCtau) of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|---|
| End point title | Area Under the Plasma Concentration-Time Curve From Time Zero to Tau (AUCtau) of Encorafenib and its Metabolite LHY746: SLI Phase ^[40] |
|-----------------|---|

End point description:

In this end point, area under the plasma concentration-time curve from time zero to the last measurable time point Tau (AUCtau) of encorafenib and its metabolite LHY746 over a dosing interval (6 hours as appropriate) of C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ng*hr/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib, n=6 LHY746, n=6 | 7490 (± 52.8) 29600 (± 73.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: AUCtau of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|--|
| End point title | AUCtau of Binimetinib and its Metabolite AR00426032: SLI Phase ^[41] |
|-----------------|--|

End point description:

In this end point, area under the plasma concentration-time curve from time zero to the last measurable time point Tau (AUCtau) of encorafenib and its metabolite LHY746 over a dosing interval (6 hours as appropriate) of C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ng*hr/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib, n=6 AR00426032, n=6 | 1440 (± 43.9) 77.9 (± 49.7) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (C_{max}) After Drug Administration of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|---|
| End point title | Maximum Observed Plasma Concentration (C _{max}) After Drug Administration of Encorafenib and its Metabolite LHY746: SLI Phase ^[42] |
|-----------------|---|

End point description:

In this end point, maximum observed plasma concentration (C_{max}) after administration of encorafenib and its metabolite LHY746 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib: C1D1, n=8 | 3210 (± 47.7) | | | |
| Encorafenib: C1D15, n=6 | 1370 (± 79.3) | | | |
| LHY746: C1D1, n=8 | 340 (± 47.2) | | | |
| LHY746: C1D15, n=6 | 1720 (± 65.3) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: C_{max} of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|--|
| End point title | C _{max} of Binimetinib and its Metabolite AR00426032: SLI |
|-----------------|--|

End point description:

In this end point, maximum observed plasma concentration (C_{max}) after administration of binimetinib and its metabolite AR00426032 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib: C1D1, n=8 | 506 (± 85.5) | | | |
| Binimetinib: C1D15, n=6 | 359 (± 40.5) | | | |
| AR00426032: C1D1, n=8 | 53.9 (± 77.8) | | | |
| AR00426032: C1D15, n=6 | 16.9 (± 54.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Minimum Observed Plasma Concentration (C_{min}) at the end of a Dosing Interval at Steady State of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|---|
| End point title | Minimum Observed Plasma Concentration (C _{min}) at the end of a Dosing Interval at Steady State of Encorafenib and its Metabolite LHY746: SLI Phase ^[44] |
|-----------------|---|

End point description:

In this end point, minimum observed plasma concentration (C_{min}) after administration of encorafenib and its metabolite LHY746 at C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib, n=6 LHY746, n=6 | 91.1 (± 88.3) 829 (± 99.3) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cmin of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|--|
| End point title | Cmin of Binimetinib and its Metabolite AR00426032: SLI |
|-----------------|--|

End point description:

In this end point, minimum observed plasma concentration (Cmin) after administration of binimetinib and its metabolite AR00426032 at C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib, n=6 AR00426032, n=6 | 47.7 (± 71.8) 3.04 (± 47.8) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Ctrough of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|---|
| End point title | Ctrough of Encorafenib and its Metabolite LHY746: SLI |
|-----------------|---|

End point description:

In this end point, measured concentration at the end of a dosing interval (Ctrough) of encorafenib and its metabolite LHY746 at C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib, n=6 | 332 (± 61.0) | | | |
| LHY746, n=6 | 1520 (± 59.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Ctrough of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|---|
| End point title | Ctrough of Binimetinib and its Metabolite AR00426032: SLI Phase ^[47] |
|-----------------|---|

End point description:

In this end point, measured concentration at the end of a dosing interval (Ctrough) of binimetinib and its metabolite AR00426032 at C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib, n=6 | 79.9 (± 56.6) | | | |
| AR00426032, n=6 | 4.71 (± 62.8) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Reach Maximum Concentration (Tmax) of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|--|
| End point title | Time to Reach Maximum Concentration (Tmax) of Encorafenib and its Metabolite LHY746: SLI Phase ^[48] |
|-----------------|--|

End point description:

In this end point, time to reach maximum concentration (Tmax) of encorafenib and its metabolite LHY746 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Encorafenib: C1D1, n=8 | 1.53 (1.47 to 3.00) | | | |
| Encorafenib: C1D15, n=6 | 1.55 (0.43 to 3.00) | | | |

| | | | | |
|--------------------|---------------------|--|--|--|
| LHY746: C1D1, n=8 | 4.33 (1.47 to 6.00) | | | |
| LHY746: C1D15, n=6 | 3.00 (2.92 to 5.73) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Tmax of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|--|
| End point title | Tmax of Binimetinib and its Metabolite AR00426032: SLI |
|-----------------|--|

End point description:

In this end point, time to reach maximum concentration (Tmax) of binimetinib and its metabolite AR00426032 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Binimetinib: C1D1, n=8 | 1.50 (1.45 to 6.08) | | | |
| Binimetinib: C1D15, n=6 | 1.55 (0.43 to 2.98) | | | |
| AR00426032: C1D1, n=8 | 1.53 (1.47 to 6.08) | | | |
| AR00426032: C1D15, n=6 | 1.58 (0.43 to 3.07) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Time of Last PK Sample (Tlast) of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|--|
| End point title | Time of Last PK Sample (Tlast) of Encorafenib and its Metabolite LHY746: SLI Phase ^[50] |
|-----------------|--|

End point description:

In this end point, time of last PK sample (Tlast) of encorafenib and its metabolite LHY746 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Encorafenib: C1D1, n=8 | 5.78 (3.00 to 6.08) | | | |
| Encorafenib: C1D15, n=6 | 24.00 (24.00 to 24.00) | | | |
| LHY746: C1D1, n=8 | 5.78 (3.00 to 6.08) | | | |
| LHY746: C1D15, n=6 | 24.00 (24.00 to 24.00) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Tlast of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|---|
| End point title | Tlast of Binimetinib and its Metabolite AR00426032: SLI |
|-----------------|---|

End point description:

In this end point, time of last PK sample (Tlast) of binimetinib and its metabolite AR00426032 at C1D1, and C1D15 were assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-------------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Binimetinib: C1D1, n=8 | 5.78 (3.00 to 6.08) | | | |
| Binimetinib: C1D15, n=6 | 12.00 (12.00 to 12.00) | | | |
| AR00426032: C1D1, n=8 | 5.78 (3.00 to 6.08) | | | |
| AR00426032: C1D15, n=6 | 12.00 (12.00 to 12.00) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Accumulation Ratio Between AUClast,ss and AUClast (RAUC) of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|--|
| End point title | Accumulation Ratio Between AUClast,ss and AUClast (RAUC) of Encorafenib and its Metabolite LHY746: SLI Phase ^[52] |
|-----------------|--|

End point description:

In this end point, accumulation ratio of encorafenib and its metabolite LHY746 calculated as: C1D15 AUC0-6 divided by C1D1 AUC0-6 was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|-----------------------------|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ratio | | | | |

| | | | | |
|---|----------------|--|--|--|
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib, n=6 | 0.468 (± 46.0) | | | |
| LHY746, n=6 | 7.25 (± 46.7) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: RAUC of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|--|
| End point title | RAUC of Binimetinib and its Metabolite AR00426032: SLI |
|-----------------|--|

End point description:

In this end point, accumulation ratio of binimetinib and its metabolite AR00426032 calculated as: C1D15 AUC0-6 divided by C1D1 AUC0-6 was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ratio | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib, n=6 | 0.877 (± 60.4) | | | |
| AR00426032, n=6 | 0.359 (± 93.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: R_{max} of Binimetinib and its Metabolite AR00426032: SLI Phase

| | |
|-----------------|--|
| End point title | R _{max} of Binimetinib and its Metabolite AR00426032: SLI Phase ^[54] |
|-----------------|--|

End point description:

In this end point, accumulation ratio of binimetinib and its metabolite AR00426032 calculated as: C1D15 C_{max} divided by C1D1 C_{max} was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with

associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ratio | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Binimetinib, n=6 | 0.818 (± 95.9) | | | |
| AR00426032, n=6 | 0.347 (± 130.9) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Accumulation Ratio Between C_{max,ss} and C_{max} (RC_{max}) of Encorafenib and its Metabolite LHY746: SLI Phase

| | |
|-----------------|--|
| End point title | Accumulation Ratio Between C _{max,ss} and C _{max} (RC _{max}) of Encorafenib and its Metabolite LHY746: SLI Phase ^[55] |
|-----------------|--|

End point description:

In this endpoint, accumulation ratio of encorafenib and its metabolite LHY746 calculated as: C_{1D15} C_{max} divided by C_{1D1} C_{max} was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 6 | | | |
| Units: ratio | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Encorafenib, n=6 LHY746, n=6 | 0.490 (± 71.8) 5.78 (± 41.7) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Ratio of AUClast Values of the Metabolite Compared to Parent (MRAUClast) of LHY746: SLI Phase

| | |
|-----------------|---|
| End point title | Ratio of AUClast Values of the Metabolite Compared to Parent (MRAUClast) of LHY746: SLI Phase ^[56] |
|-----------------|---|

End point description:

In this end point, ratio of AUClast values of the metabolite compared to parent, corrected for molecular weight, for LHY746/encorafenib at C1D1, and C1D15 was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 7 | | | |
| Units: ratio | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| C1D1, n=7 C1D15, n=6 | 0.164 (± 21.7) 2.64 (± 36.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: MRAUClast of AR00426032: SLI Phase

End point title MRAUClast of AR00426032: SLI Phase^[57]

End point description:

In this end point, ratio of AUClast values of the metabolite compared to parent, corrected for molecular weight, for AR00426032/binimetinib at C1D1, and C1D15 was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

End point type Secondary

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|---|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetinib 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 7 | | | |
| Units: ratio | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| C1D1, n=7 | 0.109 (± 54.1) | | | |
| C1D15, n=6 | 0.0494 (± 63.9) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Ratio of Cmax Values of the Metabolite Compared to Parent (MRCmax) of LHY746: SLI Phase

End point title Ratio of Cmax Values of the Metabolite Compared to Parent (MRCmax) of LHY746: SLI Phase^[58]

End point description:

In this end point, ratio of Cmax values of the metabolite compared to parent, corrected for molecular weight, for LHY746/encorafenib at C1D1, and C1D15 was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

End point type Secondary

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ratio | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| C1D1, n=8 | 0.135 (± 16.7) | | | |
| C1D15, n=6 | 1.59 (± 47.8) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: MRCmax of AR00426032: SLI Phase

| | |
|-----------------|---|
| End point title | MRCmax of AR00426032: SLI Phase ^[59] |
|-----------------|---|

End point description:

In this end point, ratio of Cmax values of the metabolite compared to parent, corrected for molecular weight, for AR00426032/ binimetinib at C1D1, and C1D15 was assessed. PK analysis set included all subjects who received at least 1 dose of any study drug and had at least 1 PK blood collection after the first dose of study drug with associated bioanalytical results. Here 'N' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable for specified rows. This endpoint was planned to be analysed in SLI phase only.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1: 0.5, 1.5, 3, 6 hours post-dose: Cycle 1 Day 15: Predose, 0.5, 1.5, 3, 6 hours (hrs.) post-dose

Notes:

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Safety-Lead in arm was planned to be analysed for this endpoint.

| | | | | |
|---|--|--|--|--|
| End point values | SLI Phase: Encorafenib 300 mg BID+Binimetini b 45 mg BID | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 8 | | | |
| Units: ratio | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| C1D1, n=8 | 0.103 (± 49.3) | | | |
| C1D15, n=6 | 0.0453 (± 53.8) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 of dosing up to 30 days after last dose of study drug in Safety Lead-in Phase (maximum up to 10.4 months) and Phase 2 (maximum up to 8.3 months)

Adverse event reporting additional description:

Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorised as serious in 1 subject and as non-serious in another, or a subject may have experienced both a serious and non-serious event.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID |
|-----------------------|--|

Reporting group description:

Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received standard combination therapy of encorafenib (450 mg orally, QD) and binimetinib (45 mg orally, BID) in 28-day cycles and subjects who were able to tolerate the encorafenib 450 mg dose further received 600 mg QD after 4 Weeks. Subjects were followed up to 30 days after last dose of study drug.

| | |
|-----------------------|---|
| Reporting group title | SLI Phase: Encorafenib 300 mg BID + Binimetinib 45 mg BID |
|-----------------------|---|

Reporting group description:

Subjects diagnosed with BRAFV600-mutant melanoma brain metastasis received combination therapy of encorafenib (300 mg orally, BID) and binimetinib (45 mg orally, BID) in 28-day cycles and continued until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, or death, whichever occurred first. Subjects were followed up to 30 days after last dose of study drug.

| Serious adverse events | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | SLI Phase: Encorafenib 300 mg BID + Binimetinib 45 mg BID | |
|---|---|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 4 / 10 (40.00%) | |
| number of deaths (all causes) | 3 | 7 | |
| number of deaths resulting from adverse events | | | |
| Vascular disorders | | | |
| Air embolism | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 10 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Paraesthesia | | | |

| | | | |
|--|---------------|-----------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocrine disorders | | | |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Phase 2: Encorafenib 450 mg QD + Binimetinib 45 mg BID | SLI Phase: Encorafenib 300 mg BID + Binimetinib 45 mg BID | |
|---|---|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 10 / 10 (100.00%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acrochordon | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 2 | |
| Neoplasm skin | | | |

| | | | |
|--|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Seborrhoeic keratosis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Vascular disorders Hypertension subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 2 | |
| General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Chills subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 3 | |
| Facial pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Oedema peripheral subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 2 | |
| Influenza like illness subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 3 | |
| Fatigue subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 6 / 10 (60.00%) 9 | |
| Pyrexia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 4 / 10 (40.00%) 4 | |
| Respiratory, thoracic and mediastinal disorders Nasal discomfort subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Wheezing | | | |

| | | | |
|---|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Respiratory tract congestion subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Psychiatric disorders Stress subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Insomnia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 3 / 10 (30.00%) 3 | |
| Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 2 / 3 (66.67%) 3 | 3 / 10 (30.00%) 4 | |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 2 / 3 (66.67%) 6 | 5 / 10 (50.00%) 8 | |
| Blood creatine phosphokinase increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 4 | |
| Blood creatinine increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 3 | |
| Lipase increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Lymphocyte count decreased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 5 | |
| Platelet count decreased | | | |

| | | | |
|---|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 2 | |
| Transaminases increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 2 | |
| Troponin T increased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 2 | |
| White blood cell count decreased subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Injury, poisoning and procedural complications Contusion subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Nervous system disorders Dizziness subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 2 | |
| Disturbance in attention subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Facial paresis subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 2 | |
| Hypoaesthesia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 3 | |
| Headache subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 3 / 10 (30.00%) 5 | |
| Lethargy | | | |

| | | | |
|--|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Memory impairment subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 1 / 10 (10.00%) 1 | |
| Neuropathy peripheral subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Paraesthesia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 2 | |
| Peripheral sensory neuropathy subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 3 | |
| Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 3 / 10 (30.00%) 4 | |
| Eye disorders Macular oedema subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 10 (0.00%) 0 | |
| Retinopathy subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Vision blurred subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Visual impairment subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Gastrointestinal disorders Abdominal distension subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Abdominal pain upper | | | |

| | | | |
|--|----------------|-----------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 2 | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 5 / 10 (50.00%) | |
| occurrences (all) | 3 | 7 | |
| Constipation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 3 / 10 (30.00%) | |
| occurrences (all) | 0 | 4 | |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 5 / 10 (50.00%) | |
| occurrences (all) | 3 | 9 | |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 10 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Gastritis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 10 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 10 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nausea | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 5 / 10 (50.00%) | |
| occurrences (all) | 3 | 8 | |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 4 / 10 (40.00%) | |
| occurrences (all) | 2 | 4 | |
| Skin and subcutaneous tissue disorders | | | |

| | | |
|-----------------------------|----------------|-----------------|
| Actinic keratosis | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Hyperkeratosis | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 2 |
| Erythema | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dermal cyst | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Melanocytic hyperplasia | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Angioedema | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Pain of skin | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Papule | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Pruritus | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 2 |
| Photosensitivity reaction | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Purpura | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 |
| Rash | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 2 |

| | | | |
|--|--------------------|----------------------|--|
| Rash macular subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Rash maculo-papular subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 4 / 10 (40.00%) 4 | |
| Rash pruritic subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Seborrhoea subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Vitiligo subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Skin disorder subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Proteinuria subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Pollakiuria subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 2 / 10 (20.00%) 3 | |
| Renal impairment subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|-----------------------------|----------------|-----------------|--|
| Arthralgia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 3 / 10 (30.00%) | |
| occurrences (all) | 0 | 4 | |
| Back pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Flank pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 2 | |
| Myositis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 10 (20.00%) | |
| occurrences (all) | 0 | 2 | |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 10 (10.00%) | |
| occurrences (all) | 1 | 1 | |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Otitis media | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Rhinitis | | | |

| | | | |
|--|--------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 10 (10.00%) 1 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 10 (20.00%) | |
| occurrences (all) | 0 | 5 | |
| Abnormal loss of weight | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 10 (20.00%) | |
| occurrences (all) | 0 | 4 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|--|
| 13 March 2020 | To revise subject eligibility criteria based on investigator feedback and changes in standard of care for the treatment of asymptomatic brain metastases. Study design was updated to allow for flexibility regarding if the high-dose regimen was not tolerated and to simplify the overall study design. |
| 07 August 2020 | To evaluate the safety, tolerability and efficacy for subjects with intra-patient dose escalation up to 600 mg QD encorafenib in Phase 2. To include update safety/risk data. Adverse events and serious adverse events revised to align with Pfizer standard operating procedures. Per Pfizer TLF reduction initiative, the safety parameters (body weight, ECOG PS, dermatologic, ECHO/MUGA and ophthalmic examination) were not summarised descriptively in the tables. |
| 04 January 2021 | 1) Clarification of Safety reporting for cardiovascular and death events; 2) Inclusion of Health Canada recommendations for additional ECG criteria that may qualify as serious adverse events. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|--------------|--|--------------|
| 02 June 2021 | Pfizer and the Steering Committee reviewed safety lead-in data and decided not to evaluate high dose combination of encorafenib + binimetinib in Phase 2 of the study. | - |

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Data for pharmacokinetic end points for "Phase 2" was not collected and analysed as sampling was insufficient to support noncompartmental analysis in subjects.

Notes: